Revenue and Profit Growth
Over the seven-year period ending March 2025, Zydus Lifesci. has steadily expanded its net sales from ₹13,165.6 crores in 2019 to ₹23,241.5 crores in 2025. This represents a compound annual growth rate (CAGR) of approximately 11.5%, reflecting the company’s successful market penetration and product portfolio expansion. The total operating income mirrors this trend, with no other operating income reported, indicating that core business activities drive revenue growth.
Operating profit (PBDIT) excluding other income rose significantly from ₹2,983.5 crores in 2019 to ₹7,058.5 crores in 2025, with the operating profit margin improving from 23.4% to 31.3%. This margin expansion suggests enhanced operational efficiency and cost management. Profit after tax (PAT) also showed a strong upward trend, increasing from ₹1,851.8 crores in 2019 to ₹4,614.8 crores in 2025, with the PAT margin rising from 14.5% to 20.4%, underscoring improved bottom-line performance.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Cost Structure and Margins
Zydus Lifesci.’s raw material costs have increased in absolute terms from ₹2,674.1 crores in 2019 to ₹4,372.9 crores in 2025, consistent with revenue growth. However, the company has managed to contain other expenses, which rose moderately from ₹3,341.6 crores to ₹6,164.4 crores over the same period. Employee costs have also increased steadily, reflecting workforce expansion and inflationary pressures.
The company’s gross profit margin has improved from 23.4% in 2019 to 30.8% in 2025, indicating better cost control and pricing power. Operating profit margins have similarly expanded, signalling operational leverage. Interest expenses have declined notably from ₹193.5 crores in 2019 to ₹165.9 crores in 2025, aided by a reduction in total debt, which fell from ₹7,901.1 crores in 2020 to zero by 2025, strengthening the company’s financial health.
Balance Sheet and Asset Quality
The company’s total assets have grown from ₹22,833.7 crores in 2020 to ₹34,857.9 crores in 2025, driven by increases in both non-current and current assets. Net block, representing fixed assets, rose from ₹12,230.5 crores in 2020 to ₹13,133.7 crores in 2025, reflecting ongoing capital expenditure. Capital work in progress and intangible assets under development have also increased, signalling investment in future growth.
Shareholders’ funds have expanded robustly from ₹10,375.7 crores in 2020 to ₹23,953.1 crores in 2025, with reserves growing substantially. The book value per share has nearly doubled from ₹101.33 in 2020 to ₹238.1 in 2025, indicating enhanced net worth and value creation for shareholders. The company’s current assets have also increased significantly, with cash and bank balances rising from ₹964.9 crores in 2020 to ₹2,956.8 crores in 2025, supporting liquidity.
Cash Flow Trends
Zydus Lifesci. has maintained positive cash flow from operating activities, which increased from ₹2,931 crores in 2020 to ₹6,776 crores in 2025. This strong cash generation supports the company’s investing activities, which have seen significant outflows, particularly in 2025, reflecting capital investments. Financing activities have fluctuated, with net inflows in 2025 contrasting with outflows in prior years, consistent with debt repayment and capital management strategies.
Overall, the company’s net cash inflow in 2025 was ₹413 crores, a positive turnaround from prior years’ fluctuations, indicating improved cash management and operational strength.
Holding Zydus Lifesci. from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary and Outlook
In summary, Zydus Lifesci. has exhibited a strong historical performance characterised by consistent revenue growth, margin expansion, and improved profitability. The company’s balance sheet has strengthened considerably, with a marked reduction in debt and a significant rise in shareholder equity. Cash flow generation remains robust, supporting ongoing investments and financial flexibility.
These trends position Zydus Lifesci. favourably within the pharmaceuticals and biotechnology sector, reflecting its capacity to sustain growth and create shareholder value. Investors may find the company’s financial discipline and operational efficiency encouraging as it continues to navigate competitive and regulatory challenges.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
